MX2021004580A - Compuestos de heteroarilcarboxamida de 5 miembros para el tratamiento del vhb. - Google Patents
Compuestos de heteroarilcarboxamida de 5 miembros para el tratamiento del vhb.Info
- Publication number
- MX2021004580A MX2021004580A MX2021004580A MX2021004580A MX2021004580A MX 2021004580 A MX2021004580 A MX 2021004580A MX 2021004580 A MX2021004580 A MX 2021004580A MX 2021004580 A MX2021004580 A MX 2021004580A MX 2021004580 A MX2021004580 A MX 2021004580A
- Authority
- MX
- Mexico
- Prior art keywords
- hbv
- membered heteroaryl
- treatment
- carboxamide compounds
- heteroaryl carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748906P | 2018-10-22 | 2018-10-22 | |
| US201962858790P | 2019-06-07 | 2019-06-07 | |
| PCT/US2019/057362 WO2020086533A1 (en) | 2018-10-22 | 2019-10-22 | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004580A true MX2021004580A (es) | 2021-09-08 |
Family
ID=68610300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004580A MX2021004580A (es) | 2018-10-22 | 2019-10-22 | Compuestos de heteroarilcarboxamida de 5 miembros para el tratamiento del vhb. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11560370B1 (enExample) |
| EP (1) | EP3870296A1 (enExample) |
| JP (1) | JP2022508953A (enExample) |
| KR (1) | KR20210095143A (enExample) |
| CN (1) | CN113195055A (enExample) |
| AU (1) | AU2019364352A1 (enExample) |
| BR (1) | BR112021007602A2 (enExample) |
| CA (1) | CA3117449A1 (enExample) |
| IL (1) | IL282433A (enExample) |
| MA (1) | MA53983A (enExample) |
| MX (1) | MX2021004580A (enExample) |
| PH (1) | PH12021550887A1 (enExample) |
| SG (1) | SG11202104086PA (enExample) |
| TW (1) | TW202028190A (enExample) |
| WO (1) | WO2020086533A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111205264A (zh) * | 2020-02-25 | 2020-05-29 | 成都睿智化学研究有限公司 | 一种合成同位羟基和甲磺酰甲基化合物的新方法 |
| WO2021216642A1 (en) * | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
| CN121248511A (zh) * | 2020-04-22 | 2026-01-02 | 组装生物科学股份有限公司 | 用于治疗hbv的5元杂芳基甲酰胺化合物 |
| EP4251622A1 (en) * | 2020-11-25 | 2023-10-04 | F. Hoffmann-La Roche AG | Aromatic bridged ring amide derivatives for the treatment and prophylaxis of hepatitis b virus infection |
| WO2023069547A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| AU2022370483A1 (en) * | 2021-10-20 | 2024-05-02 | Assembly Biosciences, Inc. | Novel crystalline forms |
| WO2023105481A1 (en) * | 2021-12-10 | 2023-06-15 | Assembly Biosciences, Inc. | Pharmaceutical compositions for the treatment of hbv |
| WO2024173196A1 (en) * | 2023-02-17 | 2024-08-22 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
| KR102827002B1 (ko) * | 2023-06-28 | 2025-06-30 | 국립순천대학교산학협력단 | 신규한 마리노바자난 화합물 및 이를 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 조성물 |
| WO2025029961A1 (en) * | 2023-07-31 | 2025-02-06 | Makscientific, Llc | Pharmaceutical compositions, and preparation and methods of use thereof |
| CN117603089A (zh) * | 2023-11-29 | 2024-02-27 | 南通瑞合达医药科技有限公司 | 一种环戊腈的合成方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002342607B2 (en) * | 2001-08-06 | 2006-10-19 | Pharmacia Italia S.P.A. | Aminoisoxazole derivatives active as kinase inhibitors |
| GB0228417D0 (en) * | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| CN101754961A (zh) | 2007-04-20 | 2010-06-23 | 先灵公司 | 嘧啶酮衍生物及其使用方法 |
| NZ596538A (en) * | 2009-05-12 | 2014-04-30 | Romark Lab Lc | Haloalkyl heteroaryl benzamide compounds |
| JP5977347B2 (ja) | 2011-07-01 | 2016-08-24 | バルーク エス．ブルームバーグ インスティテュート | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| WO2013010069A1 (en) | 2011-07-13 | 2013-01-17 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| EP2800742B1 (en) | 2012-01-06 | 2016-04-06 | Janssen Sciences Ireland UC | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b |
| EA026957B1 (ru) | 2012-08-28 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b |
| KR102271574B1 (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| HK1215030A1 (zh) | 2012-11-09 | 2016-08-12 | Indiana University Research And Technology Corporation | 用於hbv組裝效應劑的替代用途 |
| WO2014089296A2 (en) | 2012-12-06 | 2014-06-12 | Institute For Hepatitis And Virus Research | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| BR112015015584A2 (pt) | 2012-12-27 | 2017-12-12 | Baruch S Blumberg Inst | novos agentes antivirais contra infecção por hbv |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| BR112015028873A2 (pt) | 2013-05-17 | 2017-07-25 | Hoffmann La Roche | heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b |
| TWI733288B (zh) | 2013-05-17 | 2021-07-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| DK2997019T3 (en) | 2013-05-17 | 2018-12-03 | Janssen Sciences Ireland Uc | SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| HRP20180791T1 (hr) | 2013-07-25 | 2018-09-07 | Janssen Sciences Ireland Uc | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| WO2015073774A1 (en) * | 2013-11-14 | 2015-05-21 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis b infections |
| TW201620893A (zh) | 2014-02-06 | 2016-06-16 | 健生科學愛爾蘭無限公司 | 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途 |
| JP2018510159A (ja) * | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法 |
| CN105503730B (zh) * | 2015-12-25 | 2018-06-22 | 山东大学 | 吡唑类衍生物及其制备方法与应用 |
| UY37581A (es) * | 2017-02-02 | 2018-08-31 | Gilead Sciences Inc | Compuestos para el tratamiento de la infección por virus de la hepatitis b |
| CN108250112B (zh) * | 2018-01-30 | 2019-08-27 | 西北大学 | 一种1-烷基-1-芳硫基-2-(1h)-萘酮衍生物及其制备方法 |
-
2019
- 2019-10-22 CA CA3117449A patent/CA3117449A1/en active Pending
- 2019-10-22 SG SG11202104086PA patent/SG11202104086PA/en unknown
- 2019-10-22 KR KR1020217015135A patent/KR20210095143A/ko not_active Withdrawn
- 2019-10-22 EP EP19805797.8A patent/EP3870296A1/en not_active Withdrawn
- 2019-10-22 CN CN201980082985.8A patent/CN113195055A/zh active Pending
- 2019-10-22 MA MA053983A patent/MA53983A/fr unknown
- 2019-10-22 US US17/287,681 patent/US11560370B1/en active Active
- 2019-10-22 TW TW108138129A patent/TW202028190A/zh unknown
- 2019-10-22 JP JP2021547054A patent/JP2022508953A/ja active Pending
- 2019-10-22 AU AU2019364352A patent/AU2019364352A1/en not_active Abandoned
- 2019-10-22 WO PCT/US2019/057362 patent/WO2020086533A1/en not_active Ceased
- 2019-10-22 BR BR112021007602-6A patent/BR112021007602A2/pt not_active IP Right Cessation
- 2019-10-22 MX MX2021004580A patent/MX2021004580A/es unknown
-
2021
- 2021-04-19 IL IL282433A patent/IL282433A/en unknown
- 2021-04-21 PH PH12021550887A patent/PH12021550887A1/en unknown
-
2022
- 2022-11-17 US US17/989,237 patent/US12030869B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021007602A2 (pt) | 2021-07-27 |
| AU2019364352A1 (en) | 2021-06-03 |
| MA53983A (fr) | 2021-12-15 |
| PH12021550887A1 (en) | 2022-02-21 |
| US11560370B1 (en) | 2023-01-24 |
| CN113195055A (zh) | 2021-07-30 |
| WO2020086533A1 (en) | 2020-04-30 |
| EP3870296A1 (en) | 2021-09-01 |
| CA3117449A1 (en) | 2020-04-30 |
| US12030869B2 (en) | 2024-07-09 |
| TW202028190A (zh) | 2020-08-01 |
| SG11202104086PA (en) | 2021-05-28 |
| US20240150324A1 (en) | 2024-05-09 |
| JP2022508953A (ja) | 2022-01-19 |
| IL282433A (en) | 2021-06-30 |
| KR20210095143A (ko) | 2021-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550887A1 (en) | 5-membered heteroaryl carboxamide compounds for treatment of hbv | |
| PH12019502003A1 (en) | Cyclic sulfamide compounds and methods of using same | |
| PH12022552815A1 (en) | 5-membered heteroaryl carboxamide compounds for treatment of hbv | |
| JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
| PH12018500572A1 (en) | Hepatitis b core protein modulators | |
| MX2020006128A (es) | Inhibidores de la proteina de activacion de fibroblastos. | |
| JOP20170130A1 (ar) | مركبات لمعالجة عدوى فيروس التهاب الكبد الوبائي b | |
| MX2019003525A (es) | Moduladores alostericos de proteina nucleo de hepatitis b. | |
| EA201792069A1 (ru) | Производные азокана и азонана и способы лечения инфекций гепатита в | |
| MX2018005230A (es) | Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon. | |
| MX2021007602A (es) | Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b. | |
| EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
| EP4285929A3 (en) | Combination hbv therapy | |
| MX2021010145A (es) | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| MX2025009837A (es) | Compuestos de benzotia(dia)zepina para el tratamiento del vhb y el vhd | |
| WO2017161133A8 (en) | N-hydroxyisoquinolinedione inhibitors of hbv replication | |
| JOP20190214A1 (ar) | ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها | |
| EP4389222A3 (en) | Methods and compositions for the treatment of hepatitis b infection | |
| EA202191109A1 (ru) | Соединения 5-членного гетероарилкарбоксамида для лечения вируса гепатита в | |
| SG11201806433VA (en) | Composition and combined medication method for treating enterovirus infection | |
| MX2022007681A (es) | Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de tipo hepatitis b. | |
| MX2021013594A (es) | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. | |
| EA201992054A1 (ru) | Циклические сульфамидные соединения и способы их применения | |
| EA201892348A1 (ru) | Комбинации и способы, включающие ингибитор сборки капсида |